---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-004239"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2024-04-04T23:59:59+00:00"
generated_at: "2026-06-04T02:20:43.560188+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zomedica reports record FY 2023 revenue $25.2M (+33% YoY); net loss $34.5M; guides FY 2024 revenue $31-35M

## Summary
- Q4 2023 revenue $7.3M (+19% YoY); full-year revenue $25.2M vs $18.9M in 2022.
- Gross margin 69% for both Q4 and full year 2023; consumable revenue grew 41% to $16.4M.
- Net loss $34.5M ($0.035 per share) vs $17.0M ($0.017) in 2022; adjusted non-GAAP EBITDA loss $12.8M.
- Cash and securities $100.5M as of Dec 31, 2023; operating cash burn adjusted for one-time items ~$2.6M in Q4.
- FY 2024 revenue guidance $31-35M (up to 40% YoY); growth driven by recent product launches and acquisitions.

## SEC filing metadata
- accession: 0001654954-24-004239
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2024-04-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495424004239/0001654954-24-004239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495424004239/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-004239
- JSON: https://secwatch.observer/filing/0001654954-24-004239.json
- Plain text: https://secwatch.observer/filing/0001654954-24-004239.txt

## Key facts
- Earnings Releases
  Zomedica Corp. reported the fourth quarter ended December 31, 2023 results: revenue $7.3 million.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: $7.3 million
  - Result: reported results
  source text: Revenue for the fourth quarter of 2023 grew 19% to $7.3 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1684144/000165495424004239/0001654954-24-004239-index.htm
- Earnings Releases
  Zomedica Corp. reported the year ended December 31, 2023 results: revenue $25.2 million.
  - Period: the year ended December 31, 2023
  - Revenue: $25.2 million
  - Result: reported results
  source text: X-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm EXHIBIT 99.1 Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity ANN ARBOR, MI / ACCESSWIRE / April 1, 2024 / Zomedica Corp.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1684144/000165495424004239/0001654954-24-004239-index.htm
- Earnings Releases
  Zomedica Corp. reported full year 2024 results: revenue $31 to $35 million. Guidance reaffirmed.
  - Period: full year 2024
  - Revenue: $31 to $35 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Zomedica continues to expect full year revenue in the range of $31 to $35 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1684144/000165495424004239/0001654954-24-004239-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.